Cullinan Oncology to Present at the Barclays Global Healthcare Conference
Cullinan Oncology, focused on developing targeted cancer therapies, announced participation in the Barclays Healthcare Conference in Miami from March 15-17, 2022.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Cullinan Oncology, focused on developing targeted cancer therapies, announced participation in the Barclays Healthcare Conference in Miami from March 15-17, 2022. CEO Nadim Ahmed will present on March 16 at 3:20 p.m. ET. A live webcast of the presentation will be available on the investor relations website, with an archive accessible for 30 days post-event. Management will also engage in one-on-one investor meetings throughout the conference. Cullinan aims to deliver innovative treatments through internal and external collaborations.
Details
News Market Reaction – CGEM
The recorded move for CGEM in the trading session of this news was +8.91%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., March 09, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”), a biopharmaceutical company focused on developing a diversified pipeline of targeted therapies for cancer patients, today announced that it will be participating in the Barclays Healthcare Conference, being held in Miami, FL, March 15-17, 2022.
Nadim Ahmed, Cullinan’s Chief Executive Officer will be presenting on Wednesday, March 16th, at 3:20 p.m. ET
A live webcast of the presentation will be available via the Events section of the Company’s investor relations website at https://investors.cullinanoncology.com/news-events/events. Following the conclusion of the live event, an archive will be available for 30 days.
Management will also be participating in one-on-one investor meetings throughout the conference. Investors interested in scheduling a meeting with Cullinan’s management should contact their Barclays representative.
About Cullinan Oncology
Cullinan Oncology is a biopharmaceutical company that is developing a diversified pipeline of targeted therapeutic candidates across multiple modalities in order to bring important medicines to cancer patients. The Company’s strategy is to source innovation through both internal discovery efforts and external collaborations, focusing on advanced stage assets with novel technology platforms and differentiated mechanisms. Learn more about Cullinan at www.cullinanoncology.com.
Contacts:
Investor Relations
Lee Roth
+1 212.213.0006
Lroth@burnsmc.com
Jeffrey Trigilio
+1 617.410.4650
jtrigilio@cullinanoncology.com
Media
Rose Weldon
+1 215.801.7644
rweldon@cullinanoncology.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.